AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9707742 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (standard doses for 7 to 14 days)
Number of subjects: 145
Study 9707742 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (standard doses for 7 to 14 days)
Number of subjects: 145
Study 7915289 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 509
Study 3133266 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Glibenclamide (15 mg per day)
Number of subjects: 15
Study 3133266 — intervention group
Group type: COMPARATOR
Intervention: Insulin + Placebo
Number of subjects: 15
Study 31150451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional health management for three months
Number of subjects: 150
Study 31150451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transitional health management)
Number of subjects: 150
Study 28446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exergaming Program (WII Group)
Number of subjects: 30
Study 28446376 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise Program (EX Group)
Number of subjects: 30
Study 26042933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus lomustine
Number of subjects: 141
Study 26042933 — intervention group
Group type: COMPARATOR
Intervention: Lomustine single agent
Number of subjects: 141
Study 26042933 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab single agent
Number of subjects: 141
Study 23674066 — intervention group
Group type: EXPERIMENTAL
Intervention: White wheat bread fortified with bioprocessed rye bran
Number of subjects: 15
Study 23674066 — intervention group
Group type: COMPARATOR
Intervention: Native rye bran
Number of subjects: 15
Study 23674066 — intervention group
Group type: COMPARATOR
Intervention: Wholegrain rye bread
Number of subjects: 15
Study 23674066 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 15
Study 21671744 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation in functionally defined insula/middle frontal gyrus when viewing pity targets
Number of subjects: 0
Study 21671744 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation in anatomically defined bilateral anterior insula in response to positive events
Number of subjects: 0
Study 21671744 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypes' specific content
Number of subjects: 0
Study 19212103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical aerobic exercise training at 40 to 65% of heart rate reserve (%HRR) for 3.8 +/- 1.2 weeks (27 +/- 8 sessions)
Number of subjects: 21
Study 19212103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical aerobic exercise training at 40 to 65% of heart rate reserve (%HRR)
Number of subjects: 21
Study 19212103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 19212103 — intervention group
Group type: COMPARATOR
Intervention: Both groups (exercise and control)
Number of subjects: 21
Study 18062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism from an out-group member; participants reported being more defensive when evaluations were private.
Number of subjects: 0
Study 18062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism from an in-group member; participants' evaluations could be seen by an in-group audience.
Number of subjects: 0
Study 18062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism from an in-group member; high-status in-group audience.
Number of subjects: 0
Study 18062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Public evaluations of criticism from an in-group critic.
Number of subjects: 0
Study 18062847 — intervention group
Group type: COMPARATOR
Intervention: Public evaluations of criticism from an out-group critic.
Number of subjects: 0
Study 15617458 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg
Number of subjects: 180
Study 15617458 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50-100 mg
Number of subjects: 180
Study 11320384 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg)
Number of subjects: 26
Study 11320384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9298865 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic drugs
Number of subjects: 0
Study 9298865 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7509481 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO infants
Number of subjects: 40
Study 7509481 — intervention group
Group type: COMPARATOR
Intervention: Healthy term control infants
Number of subjects: 40
Study 3312204 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 200
Study 3312204 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 200
Study 31109652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once weekly (qw)
Number of subjects: 1379
Study 31109652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 1379
Study 31109652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379
Study 31109652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1379
Study 29518295 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (1.0 ml) and injectable water (1.5 ml)
Number of subjects: 20
Study 29518295 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (1 ml, 5 mg/ml) and injectable water (1.5 ml)
Number of subjects: 20
Study 25602496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing (2% chlorhexidine)
Number of subjects: 9340
Study 25602496 — intervention group
Group type: COMPARATOR
Intervention: Nonantimicrobial cloths (control)
Number of subjects: 9340
Study 24070808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Tecnis ZM900 diffractive multifocal lenses
Number of subjects: 212
Study 24070808 — intervention group
Group type: COMPARATOR
Intervention: Akreos AO monofocal lenses
Number of subjects: 212
Study 20521858 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-projection to the personal past
Number of subjects: 0
Study 20521858 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing another person's perspective
Number of subjects: 0
Study 19586971 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 65
Study 19586971 — intervention group
Group type: COMPARATOR
Intervention: Predialysis blood pressure measurements
Number of subjects: 65
Study 17596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/r (400/100mg twice daily)
Number of subjects: 23
Study 17596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/r (300/100mg once daily)
Number of subjects: 23
Study 17596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/r (400/100mg twice daily) plus Atazanavir (300mg once daily)
Number of subjects: 23
Study 17596110 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/r, Atazanavir/r, or Darunavir/r plus Atazanavir regimens
Number of subjects: 23
Study 17596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-containing regimens
Number of subjects: 23
Study 16334443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, metronidazole) for 2 weeks
Number of subjects: 20
Study 16334443 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 20
Study 11786577 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP/ABV/IMEP
Number of subjects: 996
Study 11786577 — intervention group
Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 996
Study 9800180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Conservation Program (HCP)
Number of subjects: 753
Study 9800180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 753
Study 7636076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial plus a simulation test (group 2)
Number of subjects: 413
Study 7636076 — intervention group
Group type: EXPERIMENTAL
Intervention: Drill-and-practice program plus a simulation test (group 1)
Number of subjects: 413
Study 7636076 — intervention group
Group type: COMPARATOR
Intervention: Simulation test only (group 3)
Number of subjects: 413
Study 1699689 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (hpGRF(1‐29), 1 microgram/kg i.v.)
Number of subjects: 12
Study 1699689 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal (15 micrograms/kg/h for 1 h) plus GHRH
Number of subjects: 12
Study 1699689 — intervention group
Group type: COMPARATOR
Intervention: Gal (15 micrograms/kg/h for 1 h)
Number of subjects: 12
Study 1699689 — intervention group
Group type: COMPARATOR
Intervention: Gal plus GHRH
Number of subjects: 12
Study 346192 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (Vinblastin 6 mg/m2, Thiotepa 6 mg/m2, Rufocromomycine 60 microgram/m2, Methotrexate 15 mg/m2, Procarbazine 30 mg/m2)
Number of subjects: 117
Study 346192 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 117
Study 346192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (DTIC 80 mg/kg for ten days)
Number of subjects: 117
Study 31991037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐EAUS
Number of subjects: 68
Study 31991037 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 68
Study 31991037 — intervention group
Group type: COMPARATOR
Intervention: Intra‐operative exploration
Number of subjects: 68
Study 31991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HO)‐enhanced 3D‐EAUS
Number of subjects: 68
Study 31111862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut sirolimus-eluting stents
Number of subjects: 1506
Study 31111862 — intervention group
Group type: EXPERIMENTAL
Intervention: Very thin-strut everolimus-eluting stents
Number of subjects: 1506
Study 31111862 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut zotarolimus-eluting stents
Number of subjects: 1506
Study 28950305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin (CetCis)
Number of subjects: 201
Study 28950305 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus cisplatin plus paclitaxel (CetCisPac)
Number of subjects: 201
Study 25294735 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided plasticity training starting the first week after surgery with sensory and motor re-learning using mirror visual feedback and observation of touch
Number of subjects: 37
Study 25294735 — intervention group
Group type: COMPARATOR
Intervention: Control group with re-learning starting when reinnervation could be detected
Number of subjects: 37
Study 24239156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/daily for 30 days
Number of subjects: 77
Study 24239156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/daily for 30 days
Number of subjects: 77
Study 24239156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot-derived polyphenolic fraction (BPF) 1000 mg/daily for 30 days
Number of subjects: 77
Study 24239156 — intervention group
Group type: EXPERIMENTAL
Intervention: BPF 1000 mg/daily plus rosuvastatin 10 mg/daily for 30 days
Number of subjects: 77
Study 24239156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21888660 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art strategy (education, reminders, feedback, adequate products and facilities)
Number of subjects: 900
Study 21888660 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended strategy (includes all elements of the state-of-the-art strategy plus social influence, leadership, commitment, norms, and targets)
Number of subjects: 900
Study 18649820 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable medication devices (dispensers and timers)
Number of subjects: 33
Study 17053341 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual LDT session
Number of subjects: 23
Study 17053341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LDT session
Number of subjects: 23
Study 17053341 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 23
Study 15248415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin plus clavulanic acid (2.2 g) administered 10 minutes before tonsillectomy
Number of subjects: 50
Study 15248415 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin-clavulanic acid (3 doses the day before surgery, plus one oral administration 2 hours before tonsillectomy)
Number of subjects: 50
Study 11086366 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care (n = 279) with aspirin 800 to 1000 mg plus metoclopramide 10 mg for MIDAS grade II and zolmitriptan 2.5 mg for MIDAS grade III and IV.
Number of subjects: 835
Study 11086366 — intervention group
Group type: COMPARATOR
Intervention: Step care across attacks (n = 271) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 10 mg, switching to zolmitriptan 2.5 mg if not responding in at least 2 of the first 3 attacks.
Number of subjects: 835
Study 11086366 — intervention group
Group type: COMPARATOR
Intervention: Step care within attacks (n = 285) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 20 mg, escalating to zolmitriptan 2.5 mg if not responding after 2 hours.
Number of subjects: 835
Study 11086366 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care (n = 279)
Number of subjects: 835
Study 11086366 — intervention group
Group type: COMPARATOR
Intervention: Step care across attacks (n = 271)
Number of subjects: 835
Study 11086366 — intervention group
Group type: COMPARATOR
Intervention: Step care within attacks (n = 285)
Number of subjects: 835
Study 9282965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 206
Study 9282965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 8442969 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 0.5 mg/kg after no pretreatment
Number of subjects: 50
Study 8442969 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after d‐tubocurarine 0.05 mg/kg IV 3 minutes before
Number of subjects: 50
Study 8442969 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after chlorpromazine 0.1 mg/kg IV 3 minutes before
Number of subjects: 50
Study 8442969 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after alpha‐tocopherol (vitamin E) 600 mg in three divided doses orally at 6‐hour intervals
Number of subjects: 50
Study 8442969 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after aspirin 600 mg orally 1 hour before
Number of subjects: 50
Study 3089491 — intervention group
Group type: EXPERIMENTAL
Intervention: linoleic acid
Number of subjects: 22
Study 3089491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 31558086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet (lentils, beans, split peas, and chickpeas) with health counseling and aerobic exercise
Number of subjects: 61
Study 31558086 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) diet with health counseling and aerobic exercise
Number of subjects: 61
Study 28549873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Betadine (Povidone‐iodine)
Number of subjects: 204
Study 28549873 — intervention group
Group type: COMPARATOR
Intervention: Topical Clotrimazole
Number of subjects: 204
Study 27464488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Number of subjects: 260
Study 27464488 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 260
Study 27464488 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity and Dietary Intervention
Number of subjects: 260
Study 27464488 — intervention group
Group type: COMPARATOR
Intervention: Less Intensive Intervention
Number of subjects: 260
Study 24435584 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR + coach
Number of subjects: 71
Study 24435584 — intervention group
Group type: COMPARATOR
Intervention: IVR + no-coach
Number of subjects: 71
Study 23439339 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 20
Study 21474462 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA)
Number of subjects: 0
Study 21474462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18424298 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hematoma evacuation
Number of subjects: 10
Study 18424298 — intervention group
Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 10
Study 16515902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 150
Study 16515902 — intervention group
Group type: COMPARATOR
Intervention: Heparin with protamine reversal
Number of subjects: 150
Study 14747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen blockade with 4 cycles of immediate chemotherapy
Number of subjects: 30000
Study 14747047 — intervention group
Group type: COMPARATOR
Intervention: Androgen blockade with delayed chemotherapy
Number of subjects: 30000
Study 11109313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with 17-beta-estradiol and noretisterone acetate, TTS for 3 months.
Number of subjects: 53
Study 11109313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT) for 3 months.
Number of subjects: 53
Study 9195357 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypotension alone
Number of subjects: 30
Study 9195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution plus controlled hypotension
Number of subjects: 30
Study 9195357 — intervention group
Group type: COMPARATOR
Intervention: Hemodilution alone
Number of subjects: 30
Study 8266412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 0
Study 8266412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 0
Study 3313739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 750 mg, sulfadoxine 1500 mg and pyrimethamine 75 mg (MSP) single oral dose
Number of subjects: 66
Study 3313739 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg/kg tds X 7 days oral therapy)
Number of subjects: 66
Study 31900583 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 3217
Study 31900583 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 3217
Study 30269900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331
Study 30269900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 30269900 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD presence
Number of subjects: 2331
Study 27327024 — intervention group
Group type: COMPARATOR
Intervention: High-CHO (HCHO): 10 g·kg CHO, 2.5 g·kg protein, and 0.8 g·kg fat for the entire trial period
Number of subjects: 10
Study 27327024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-CHO but high-fat availability (HFAT): 2.5 g·kg CHO, 2.5 g·kg protein, and 3.5 g·kg fat for the entire trial period
Number of subjects: 10
Study 27327024 — intervention group
Group type: COMPARATOR
Intervention: High-CHO (HCHO)
Number of subjects: 10
Study 27327024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-CHO but high-fat availability (HFAT)
Number of subjects: 10
Study 27327024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO (HCHO) and Reduced-CHO but high-fat availability (HFAT)
Number of subjects: 10
Study 24293578 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day of prednisolone for 6 weeks
Number of subjects: 125
Study 24293578 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 125
Study 22050499 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 60
Study 22050499 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 18801638 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (intervention interview included an educational paragraph)
Number of subjects: 473
Study 18801638 — intervention group
Group type: COMPARATOR
Intervention: Current therapy for cardiac arrest (not specified as intervention or control)
Number of subjects: 473
Study 18359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of the magnocellular pathway through psychophysical manipulations (red background, equiluminant background, flicker or motion adaptation)
Number of subjects: 0
Study 17042844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 80
Study 17042844 — intervention group
Group type: COMPARATOR
Intervention: Ilio-inguinal nerve block
Number of subjects: 80
Study 12822009 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 6
Study 10609592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 1600
Study 10609592 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 1600
Study 7867183 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab 0.25 mg/kg
Number of subjects: 6
Study 2026760 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose 0.6 mU/kg‐min
Number of subjects: 12
Study 2026760 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose 5.0 mU/kg‐min
Number of subjects: 12
Study 7388581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 93
Study 7388581 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 93
Study 7388581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 93
Study 30694452 — intervention group
Group type: EXPERIMENTAL
Intervention: Debiasing checklist
Number of subjects: 61
Study 30694452 — intervention group
Group type: EXPERIMENTAL
Intervention: Content (knowledge) checklist
Number of subjects: 61
Study 30694452 — intervention group
Group type: COMPARATOR
Intervention: Control (no checklist)
Number of subjects: 61